EUCTR2023-001124-42-Outside-EU/EEA进行中（未招募）1 期
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents - A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Able and willing to provide informed consent (and assent, as applicable) voluntarily signed by participant (and guardian, as applicable).
- •2. Males or females, 12 to <65 years of age.
- •3. Generally healthy, in the opinion of the investigator, based on medical history, physical examination, and screening laboratory assessments.
- •4. Women who are either: (i) Not of childbearing potential (CBP): pre-menarche, surgically sterile (at least six weeks post bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or postmenopausal (defined as a history of =12 consecutive months without menses prior to randomization in the absence of other pathologic or physiologic causes, following cessation of exogenous sex-hormonal treatment) or (ii) Meeting all the below criteria: Negative serum pregnancy test at screening visit, Negative urine pregnancy test immediately prior to dosing at Day 1, Using an acceptable method of contraception (if women of CBP) for the duration of participation, such as hormonal contraceptives (eg, implants, pills, patches) initiated =30 days prior to dosing, intrauterine device (IUD) inserted =30 days prior to dosing, double barrier type of birth control (male condom with female diaphragm, male condom with cervical cap), Abstinence is acceptable only for adolescents (12 to <18 years old) who are not sexually active.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 245
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2905
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Currently pregnant, breastfeeding, or planning to become pregnant during the study.
- •2. Body Mass Index (BMI) =35 kg/m2.
- •3. Positive laboratory evidence of current infection with human immunodeficiency virus (HIV-1, HIV-2), hepatitis C virus (HCV) or hepatitis B virus (HBV).
- •4. History of severe allergic reaction or anaphylaxis to any component of the vaccine.
- •5. History of any known congenital or acquired immunodeficiency that could impact response to vaccination (eg, leukemia, lymphoma, generalized malignancy, functional or anatomic asplenia, alcoholic cirrhosis).
- •6. Prior receipt or anticipated use of systemic immunomodulatory or immunosuppressive medications from six months prior to screening through Day 22. Note: For systemic corticosteroids, use at a dose or equivalent dose of 20 mg of prednisone daily for 14 days or more within three months of screening through Day 22 is exclusionary. The use of inhaled, intranasal, topical, ocular, or intraocular steroids is allowed.
- •7. Receipt or anticipated receipt of blood or blood-derived products from 90 days prior to screening through Day 22.
- •8. Acute disease within the last 14 days (participants with an acute mild febrile illness can be considered for a deferral of vaccination two weeks after the illness has resolved and treatment has been completed).
- •9. Clinically significant cardiac, pulmonary, rheumatologic, or other chronic disease, in the opinion of the investigator. This may include chronic illness requiring hospitalization in the last 30 days prior to screening.
- •10. Enrollment in an interventional study and/or receipt of another investigational product from 30 days prior to screening through the duration of study participation.
- •11. Receipt or anticipated receipt of any vaccine from 30 days prior to Day 1 through Day 22.
- •12. Evidence of substance abuse that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study.
- •13. Prior receipt of an investigational CHIKV vaccine/product.
- •14. Any other medical condition that, in the opinion of the investigator, could adversely impact the participant's participation or the conduct of the study.
研究者
相似试验
已完成
3 期
A clinical study to evaluate safety and compare immune responses of two formulations of a combined 5-in-1 DTwP-HepB-Hib vaccine in childreCTRI/2018/12/016692Shantha Biotechnics Pvt Ltd460
Enrolling By Invitation
3 期
Phase 3 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac COVID-19 vaccine boost in comparison to a viral vector-based COVID-19 vaccinesHealthy male and female subjectsTCTR20221026004The Government Pharmaceutical Organization4,000
尚未招募
3 期
Phase 3 study, to evaluate the safety and immunogenicity of HXP-GPOVac vaccine in comparison to AstraZeneca's AZD1222 COVID-19 vaccineHealthy male and female subjectsTCTR20220120002The Government Pharmaceutical Organization4,000
已完成
不适用
Immunogenicity and safety of a Meningococcus B Brazilian vaccineISRCTN15065741Bio-Manguinhos/Fiocruz (Brazil)240
进行中（未招募）
1 期
A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study of Nirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants With COVID-19 Who Are at Risk of Progression to Severe DiseaseSARS-CoV-2 InfectionMedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-000075-39-HUPfizer Inc.142